Vical Is Vital On Wall Street After Adenoviral Vector Problems
Vical's "naked DNA" vectorless gene therapy technology helped the company outstrip a strong market for biotech stocks and post a 50% gain for the month of November.
You may also be interested in...
Genzyme's $350 mil. acquisition of Cell Genesys represents a vote of confidence in gene therapy after concerns about the death of a clinical trial subject.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials